Morningstar Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.67M Hold
60,529
0.23% 107
2026
Q1
$3.67M Buy
60,529
+2,750
+5% +$160K 0.23% 107
2025
Q4
$3.12M Sell
57,779
-104,607
-64% -$5.03M 0.18% 120
2025
Q3
$7.32M Buy
162,386
+148,622
+1,080% +$6.94M 0.27% 93
2025
Q2
$637K Buy
13,764
+2,573
+23% +$126K 0.06% 101
2025
Q1
$683K Sell
11,191
-8,775
-44% -$511K 0.06% 58
2024
Q4
$1.13M Sell
19,966
-1,527
-7% -$85.3K 0.09% 62
2024
Q3
$1.13M Sell
21,493
-1,178
-5% -$55.3K 0.11% 77
2024
Q2
$942K Buy
22,671
+716
+3% +$32K 0.1% 87
2024
Q1
$1.19M Hold
21,955
0.13% 73
2023
Q4
$1.13M Buy
21,955
+14,606
+199% +$767K 0.13% 73
2023
Q3
$427K Buy
7,349
+1,035
+16% +$63.4K 0.06% 107
2023
Q2
$404K Hold
6,314
0.05% 111
2023
Q1
$438K Buy
6,314
+712
+13% +$50.2K 0.06% 60
2022
Q4
$403K Buy
+5,602
New +$422K 0.07% 64

Other funds holding BMY

Morningstar Investment Management's BMY Position: Q2 2026 in Review

Morningstar Investment Management held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 60,529 shares worth $3.67M. The position accounts for 0.23% of the portfolio, ranked #107.

Morningstar Investment Management first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $7.32M in Q3 2025. 1,306 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Morningstar Investment Management held 60,529 shares of Bristol-Myers Squibb worth $3.67M as of Q2 2026.
  • Morningstar Investment Management left its Bristol-Myers Squibb share count unchanged in Q2 2026.
  • Bristol-Myers Squibb made up 0.23% of Morningstar Investment Management's portfolio in Q2 2026, its #107 holding.
  • Morningstar Investment Management first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
  • Morningstar Investment Management's Bristol-Myers Squibb position peaked at $7.32M in Q3 2025.
  • 1,306 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Morningstar Investment Management's 13F filing for Q2 2026, filed 21 Jul 2026.